GlassScriptPhysician profile
Vincent Donnabella
NPI 1710988860
$6,051.35
in general payments reported to CMS, 2019-2025
36 companies · $916 in 2025
The $916 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $648 · 2021: $911 · 2022: $606 · 2023: $996 · 2024: $993 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,905.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,041.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $917.52 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.35 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $403.23 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $339.04 | 2019-2024 | Yupelri |
| Amgen INC. | $301.80 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $241.55 | 2019-2024 | Dupixent |
| Inspire Medical Systems, INC. | $144.90 | 2024 | Inspire |
| Grifols USA, LLC | $123.33 | 2020-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $86.47 | 2025 | Yupelri |
| Genzyme Corporation | $77.24 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $68.07 | 2020-2021 | |
| Incyte Corporation | $68.04 | 2021-2022 | |
| Octapharma USA, INC. | $64.41 | 2020-2021 | |
| Axsome Therapeutics, INC. | $63.52 | 2023-2024 | Sunosi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.25 | 2019 | |
| Merck Sharp & Dohme LLC | $41.78 | 2019-2023 | |
| Circassia INC. | $40.83 | 2019 | |
| Electromed, INC. | $39.96 | 2023 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $38.16 | 2021 | |
| Ani Pharmaceuticals, INC. | $37.64 | 2024 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $36.02 | 2025 | Ohtuvayre |
| Philips North America LLC | $31.22 | 2022-2024 | (Ak6) Vest Therapy |
| Vifor Pharma, INC. | $29.80 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2022-2024 | Aralast |
| Mallinckrodt Hospital Products INC. | $28.82 | 2022-2023 | Acthar |
| Ambu INC. | $28.41 | 2020 | |
| Genentech USA, INC. | $27.13 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.33 | 2020 | |
| Advanced Respiratory, INC | $18.99 | 2019 | |
| Pfizer INC. | $16.53 | 2024 | |
| Phadia US INC. | $12.83 | 2023 | Immunocap |
| Astellas Pharma US INC | $12.23 | 2019 | |
| Optinose US, INC. | $11.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.23 | 2019 | |
| Pharming Healthcare, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Donnabella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.